OncoDiscover Brochure Literature 9 March 2026 OncoDiscover Brochure Detailed Brochure for OncoDiscover Download Brochure Never Miss a Breakthrough. Get the latest news and innovations from OncoDiscover delivered straight to your inbox. Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test

The OncoDiscover® CTC Test is India's first DCG(I) approved blood test that detects circulating tumor cells to reveal early cancer spread before it's visible. Identify CTCs with a simple blood test. Detect the cells before they spread. The OncoDiscover® CTC Test detects circulating tumor cells in the bloodstream using a simple blood sample—helping reveal whether cancer may be spreading before it becomes visible through conventional methods. Book a test A diagnostic test that is patented globally and approved by DCG(I) Know more Requires just 5ml of blood The OncoDiscover® CTC Test requires only 5ml of the patient’s blood sample. Can be done frequently The OncoDiscover® CTC Test can be done at regular intervals for continuous monitoring and arriving at therapy decisions. No exposure to radiation The test is conducted on patient’s blood sample at our diagnostic laboratory. Patients don’t have to go through any physically painful and emotionally stressful tests that use radiations. Convenient. No fasting. Our registered phlebotomists can collect the blood samples from patient’s home. There are no restrictions with regards to fasting or medication for the blood sample. Leading institutions use the OncoDiscover® CTC Test OncoDiscover® CTC Test is being widely accepted by the oncology fraternity and is used for monitoring and effective therapy decisions. Fighting cancer. One cell at a time. One in a billion cells. Even a single tumor cell can cause cancer relapse and can lead to metastasis (spread of cancer). OncoDiscover® CTC Test detects, with pinpoint accuracy, those pesky cells whose presence, even a single one of them, leads to the spread of cancer even after the patient’s treatment has been completed and the patient seems to have recovered. Cost-effective The OncoDiscover® CTC Test has been developed with a goal of making it affordable and accessible to everyone who is in need of it. It is 50% cheaper than any other test to diagnose cancer cells. Time Saving At OncoDiscover® laboratory the diagnostic test are run on the blood samples of the patients. Typically a complete run cycle is completed within a weeks time followed by analysis by scientific experts. Accurate The OncoDiscover® CTC Test can identify pesky tumor cells amongst billions of cells in the blood samples from the patients. It is as accuarate as counting one in a billion cells from the blood sample. Safe The OncoDiscover® CTC Test is absolutely safe. Only 5 ml of patients blood sample is collected and subject to the diagnostic runs. Patients don’t need to through any other tests including that involving radiations. Convenient The OncoDiscover® CTC Test is a simple blood test. Just book the CTC Test online or through a phone call. Our registered phlebotomists can collect the blood samples from patient’s home. Pain-free The patient doesn’t have to go through any medical procedure or go through any tissue biopsy. All that it needs is patients blood samples - ensuring its physically and emotionally pain-free for the patient. Why choose us? Our approach is grounded in rigorous research, advanced platforms, and a commitment to meaningful outcomes. Know more 11000+ Patients Served 450+ Doctors Trust Us 100+ Publications 13+ Years of Excellence Patented Techologies Proprietary innovations designed to deliver precision, reliability, and real-world impact. View Patents Regulatory Approved Regulatory-approved solutions built to meet the highest standards of safety, compliance, and clinical integrity. View Credentials Accreditations/ Patents DCG(I) Approved License No. MFG/IVD/2019/000031 ISO 13485:2016 certified by INTERTEK; Certificate No. 0140783 Innovator of the Year 2019 Department of Biotechnology, Government of India Patented International Application No. PCT/IB2016/050779 Our Publications In collaboration with researchers and thought leaders around the world, OncoDiscover® combines scientific expertise with cutting-edge innovation to advance the frontiers of cancer care. The research behind the technology is supported by 100+ scientific publications presented at leading global forums such as ASCO, AACR, ESMO, ISLB, etc View all publications Latest from Actorius Explore the latest updates, research perspectives, announcements, and stories shaping our work. View all updates Publications ASCO 2026 : Association of circulating tumor cells with PD-L1 expression and clusters in confirmative tumor thrombus in selective solid cancers. 17 March 2026 Read More Press Release Actorius Innovations pioneers' oncology care with its OncoDiscover and OncoMetastat solutions 17 March 2026 Read More Publications ASCO 26: Assessment of circulating tumor cells and clusters expressing PD-L1 in urological cancers 17 March 2026 Read More OncoDiscover® in Action Stay updated with our latest events, scientific discussions, collaborations, and milestones that continue to shape the future of cancer research and innovation. View all events Events AACR 2026 Highlights | April 17-22 | San Diego, California 23 April 2026 Read More Events Meeting with our International KOLs 20 February 2026 Read More Events ISLB 2025 | 1-3 November 2025 3 November 2025 Read More Be informed. Be a fighter. Patient Testimonials Hear directly from patients about their experiences and outcomes with our innovations. View all testimonials Sharvari Pantekar Breast Cancer Survivor Rupali Gunjikar Neuro-endocrine Cancer Survivor What’s More Painful than a Cancer Relapse A cancer Relapse not Caught in Time. A cancer Relapse not Caught in Time. A cancer Relapse not Caught in Time. A cancer Relapse not Caught in Time. In the News Explore how OncoDiscover® is making headlines in cancer research and diagnostics. View all mentions Actorius Innovations pioneers' oncology care with its OncoDiscover and OncoMetastat solutions Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control 17 March 2026 Read More Actorius Innovations pioneers' oncology care with its OncoDiscover and OncoMetastat solutions Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control 17 March 2026 Read More Actorius Innovations pioneers' oncology care with its OncoDiscover and OncoMetastat solutions Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control 17 March 2026 Read More © Copyright Actorius Innovations and Research Remission gives you hope. This test gives you confidence. OncoDiscover detects circulating tumour cells early, enabling timely decisions, better control, and renewed confidence. Book a test Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test

Discover our groundbreaking research in Oncology. Explore our publications to see research that matters. Stay informed with our latest insights. Expert Insights Insights that shape the domain Deep-dive into expert opinions, scientific perspectives, and thought leadership shaping the future of cancer care. View more TEDx Talk — Capturing cancer cells-Uncovering secrets for treatments by Aravindan Vasudevan – CEO, Actorius Date: February 28, 2023 TedxTalks Link Conference Title: CTC National Oncology Conference Date: July 23, 2022 | Venue: Taj Vivanta, Hinjewadi, Pune Launch of OncoDiscover® at the hands of Hon’ble Dr. Harsh Vardhan, Health Minister - Government of India Date: September 12, 2019 | Venue: Actorius Office, Pune Regular Information = Actionable Insights Helping the world to become cancer-free Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test

Explore the latest resources from OncoDiscover® CTC Test, India's first DCG(I) approved blood test that detects circulating tumor cells to reveal early cancer spread before it's visible. Resources Latest from Actorius Explore the latest updates, research perspectives, announcements, and stories shaping our work. Manuscripts Publications Case Study Literature Events 17 March 2026 Publications ASCO 2026 : Association of circulating tumor cells with PD-L1 expression and clusters in confirmative tumor thrombus in selective solid cancers. Study shows circulating tumor cells with PD-L1 expression in tumor thrombus patients, indicating active dissemination and potential metastatic risk. Read More 17 March 2026 Press Release Actorius Innovations pioneers' oncology care with its OncoDiscover and OncoMetastat solutions Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control Read More 17 March 2026 Publications ASCO 26: Assessment of circulating tumor cells and clusters expressing PD-L1 in urological cancers High prevalence of PD-L1–positive circulating tumor cells in urological cancers, especially prostate cancer, indicating minimal residual disease and recurrence risk. Read More 17 March 2026 Press Release Actorius Innovations pioneers' oncology care with its OncoDiscover and OncoMetastat solutions Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control Read More 17 March 2026 Publications ASCO 2026: Comparative enumeration of circulating tumor cells with PD-L1 over expression using anti EpCAM antibody to N-Cadherin in solid cancers Dual EpCAM and N-cadherin profiling improves circulating tumor cell detection, enhancing minimal residual disease surveillance and identifying metastasis-prone cells. Read More 17 March 2026 Publications AACR 2026: Over expressing PD-L1 circulating tumor cells with clusters in prostate cancer patients Study shows high prevalence of PD-L1–positive circulating tumor cells in prostate cancer, highlighting their value for monitoring disease progression and immune evasion. Read More 17 March 2026 Press Release Actorius Innovations pioneers' oncology care with its OncoDiscover and OncoMetastat solutions Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control Read More 17 March 2026 Publications ASCO 2026: Continual depletion of circulating tumor cells using an automated device enriched with affinity glass bead substrates in breast and CRC patient's whole blood. Automated OncoMetastat device captures and depletes CTCs in colorectal and breast cancer, aiding detection of minimal residual disease and metastasis risk. Read More 17 March 2026 Publications AACR 2026: Depletion of circulating tumor cells using an automated device using non-hemolytic affinity-based substrates Actorius Innovations presents accepted research abstracts at the AACR Annual Meeting 2026, highlighting advances in cancer diagnostics, therapeutics and liquid biopsy. Read More 14 March 2026 Press Release Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control Actorius Innovations and Research Pvt Ltd, a pioneering Indo-US biotechnology company revolutionizing oncology through advanced circulating tumor cell (CTC) technologies, continues to make significant strides under the visionary leadership of Dr. Jayant Khandare, Founder, Managing Director, and Chief Scientific Officer. Read More 9 March 2026 Literature OncoDiscover PD-L1 whitepaper Fighting cancer. One cell at a time. Read More 9 March 2026 Literature OncoDiscover Brochure Detailed Brochure for OncoDiscover Read More 9 March 2026 Literature OncoDiscover TRF Test Requisition Form Read More 7 March 2026 Publications AACR 2020: Clinical correlation of circulating tumor cells as a blood marker in Indian head and neck cancer patients. A study of 350 Indian HNC patients confirms CTCs correlate with nodal stage and aggressive features, validating their use as a clinical staging marker. Read More 5 February 2026 Press Release Actorius and ACTREC Partner to Advance Clinical Cancer Research. A collaborative research initiative to study the practical utility of Circulating Tumor Cells and their capture and depletion from patient's blood as possible aid to adjunct therapeutics. Read More 27 January 2026 Manuscript Manuscript: Real-Time Therapy Response Monitoring Using Surface Biomarkers on Circulating Tumor Cells Circulating tumor cells (CTCs), cancer cells shed from primary tumors into the bloodstream, are emerging as dynamic, non-invasive biomarkers for real-time cancer monitoring, especially when tissue biopsies are inaccessible or inadequate... Read More 3 November 2025 Publications PD-L1 over-expression on Circulating Tumor Cells in Endometrial Cancer Patients Khandare J, Ghadyalpatil N, Raja T, Velukuru S, Jadhav V, Satape R, Shinde S, Ashturkar A, Dattatreya P, Vasudevan A Actorius Innovations And Research, Pune, Maharashtra, India; Apollo Cancer Institute, Hyderabad, Telangana, India; Apollo Cancer Centre, Chennai, Tamil Nadu, India; Aster CMI Hospital, Bangaluru, Karnataka, India; Renova Soumya Cancer Center, Hyderabad, Telangana, India. Read More 3 November 2025 Publications Assessment of PD-L1 Expression on Circulating Tumor Cells and Clusters in Gastric Cancer Patients Circulating tumor cells with PD-L1 expression and clusters are common in gastric cancer, indicating minimal residual disease and recurrence risk. Read More 3 November 2025 Publications Automated Continual Flow Device to Deplete Circulating Tumor Cells using Spiral Cartridge Mediated by Antibody and Transferrin Glass Substrate Automated OncoMetastat device captures and depletes circulating tumor cells from whole blood safely, supporting extracorporeal cancer therapy and monitoring. Read More 3 November 2025 Publications Association of Circulating Tumor Cell Dynamics with Patient-Reported Cancer Worry in Post-Surgical Breast Cancer Patients Circulating tumor cell monitoring before and after breast cancer surgery reveals minimal residual disease and correlates with post-surgical cancer worry. Read More First Prev 1 Page 1 Next Last Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test

Explore scientific publications from Actorius covering circulating tumor cells, liquid biopsy technologies, and innovations in cancer diagnostics and monitoring. Publications Research That Shapes the Future of Oncology Access studies, scientific papers, and published findings advancing cancer diagnostics and care. 17 March 2026 Read More ASCO 2026 : Association of circulating tumor cells with PD-L1 expression and clusters in confirmative tumor thrombus in selective solid cancers. Study shows circulating tumor cells with PD-L1 expression in tumor thrombus patients, indicating active dissemination and potential metastatic risk. 17 March 2026 Read More ASCO 26: Assessment of circulating tumor cells and clusters expressing PD-L1 in urological cancers High prevalence of PD-L1–positive circulating tumor cells in urological cancers, especially prostate cancer, indicating minimal residual disease and recurrence risk. 17 March 2026 Read More ASCO 2026: Comparative enumeration of circulating tumor cells with PD-L1 over expression using anti EpCAM antibody to N-Cadherin in solid cancers Dual EpCAM and N-cadherin profiling improves circulating tumor cell detection, enhancing minimal residual disease surveillance and identifying metastasis-prone cells. 17 March 2026 Read More AACR 2026: Over expressing PD-L1 circulating tumor cells with clusters in prostate cancer patients Study shows high prevalence of PD-L1–positive circulating tumor cells in prostate cancer, highlighting their value for monitoring disease progression and immune evasion. 17 March 2026 Read More ASCO 2026: Continual depletion of circulating tumor cells using an automated device enriched with affinity glass bead substrates in breast and CRC patient's whole blood. Automated OncoMetastat device captures and depletes CTCs in colorectal and breast cancer, aiding detection of minimal residual disease and metastasis risk. 17 March 2026 Read More AACR 2026: Depletion of circulating tumor cells using an automated device using non-hemolytic affinity-based substrates Actorius Innovations presents accepted research abstracts at the AACR Annual Meeting 2026, highlighting advances in cancer diagnostics, therapeutics and liquid biopsy. 7 March 2026 Read More AACR 2020: Clinical correlation of circulating tumor cells as a blood marker in Indian head and neck cancer patients. A study of 350 Indian HNC patients confirms CTCs correlate with nodal stage and aggressive features, validating their use as a clinical staging marker. 3 November 2025 Read More PD-L1 over-expression on Circulating Tumor Cells in Endometrial Cancer Patients Khandare J, Ghadyalpatil N, Raja T, Velukuru S, Jadhav V, Satape R, Shinde S, Ashturkar A, Dattatreya P, Vasudevan A Actorius Innovations And Research, Pune, Maharashtra, India; Apollo Cancer Institute, Hyderabad, Telangana, India; Apollo Cancer Centre, Chennai, Tamil Nadu, India; Aster CMI Hospital, Bangaluru, Karnataka, India; Renova Soumya Cancer Center, Hyderabad, Telangana, India. 3 November 2025 Read More Assessment of PD-L1 Expression on Circulating Tumor Cells and Clusters in Gastric Cancer Patients Circulating tumor cells with PD-L1 expression and clusters are common in gastric cancer, indicating minimal residual disease and recurrence risk. 3 November 2025 Read More Automated Continual Flow Device to Deplete Circulating Tumor Cells using Spiral Cartridge Mediated by Antibody and Transferrin Glass Substrate Automated OncoMetastat device captures and depletes circulating tumor cells from whole blood safely, supporting extracorporeal cancer therapy and monitoring. 3 November 2025 Read More Association of Circulating Tumor Cell Dynamics with Patient-Reported Cancer Worry in Post-Surgical Breast Cancer Patients Circulating tumor cell monitoring before and after breast cancer surgery reveals minimal residual disease and correlates with post-surgical cancer worry. 17 October 2025 Read More Circulating Biomarkers Reveal their Complementary Association in Primary and Metastatic Colorectal Cancer Patients Combined CTC and ctDNA analysis reveals strong prognostic value for monitoring progression and metastasis in colorectal cancer patients. 16 September 2025 Read More PD-L1 overexpression on circulating tumor cells and CTC clusters: A potential biomarker across solid carcinomas Correlation of CTC detection, PD-L1 expression, and CTC clusters highlights biomarkers for minimal residual disease and cancer progression monitoring. 16 September 2025 Read More Profiling of PD-L1 and HER2 over expression on cancer cells using AI based macro-driven automation AI-based image analysis rapidly profiles circulating tumor cells, quantifying morphology and biomarkers like PD-L1 and HER2 for cancer research. 3 June 2025 Read More PD-L1 expression on circulating tumor cells and CTC clusters as a minimal cellular disease in breast cancer patients. This breast cancer study shows high prevalence of PD-L1–positive circulating tumor cells, supporting their role in minimal residual disease and metastasis risk. 3 June 2025 Read More Circulating tumor cells and clusters exhibiting expression of PD-L1 in colorectal patients. High prevalence of PD-L1–positive circulating tumor cells in colorectal cancer highlights their role in minimal residual disease and recurrence monitoring. 3 June 2025 Read More Use of dynamic blood flow device with conjugated affinity ligands on glass substrate to capture circulating tumor cells in cancer patients. Continuous-flow 3D glass substrate device safely captures circulating tumor cells, demonstrating potential to reduce metastasis and improve cancer survival. 3 June 2025 Read More Quadrant of co-occurrence of circulating tumor DNA and PD-L1 expression on circulating tumor cells in monitoring disease aggressiveness and metastasis in lung cancer. Combined ctDNA and PD-L1–positive CTC analysis improves monitoring of metastasis, minimal residual disease, and treatment response in lung cancer. 3 June 2025 Read More Comparative analysis of circulating tumor cell distribution with PD-L1 expression in baseline and follow ups patients across cancer types. This multi-cancer study shows CTC and PD-L1 prevalence across Indian patients, supporting minimal residual disease monitoring and personalized cancer care. 9 May 2025 Read More Accounts of circulating tumor cells and CTC clusters with PD-L1 expression in sarcoma patients Study shows circulating tumor cells with PD-L1 expression and clusters in sarcoma, indicating minimal residual disease and need for long-term monitoring. First Prev 1 Page 1 Next Last Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test

Discover the Actorius Research Centre, where scientists advance cancer diagnostics, liquid biopsy technologies, and innovative oncology solutions. Research Centre We are in pursuit of identifying and developing life-saving solutions for global healthcare problems with a focus on cancer diagnostics and cure. A diagnostic test that is patented globally and approved by DCG(I) Know more Requires just 10ml of blood The OncoDiscover® CTC Test requires only 5ml of the patient’s blood sample. Can be done frequently The OncoDiscover® CTC Test can be done at regular intervals for continuous monitoring and arriving at therapy decisions. No exposure to radiation The test is conducted on patient’s blood sample at our diagnostic laboratory. Patients don’t have to go through any physically painful and emotionally stressful tests that use radiations. Convenient. No fasting. Our registered phlebotomists can collect the blood samples from patient’s home. There are no restrictions with regards to fasting or medication for the blood sample. Our story so far An innovation-driven organisation 11000+ Patients Served 100+ Scientists 100+ Publications 1000+ Patients Served Know more Mission, Vision & Purpose Innovating with Intent Our mission, vision, and purpose reflect our commitment to meaningful progress and measurable outcomes. Mission To develop innovative methodologies to develop diagnostic tests that provide early indicators of oncogenesis and enable informed treatment strategies. Vision To collectively advance and improve human health by developing biomedical innovations into practical applications that have wider reach, accessibility and affordability. Purpose To positively impact everyone, by developing solutions that have reduced time to decision making and providing precise information for a chosen course of action. Our Values What We Stand For Our values define our commitment to rigorous science, responsibility, and meaningful impact. Work on challenges with cutting-edge science and innovation. Work towards making it accessible and affordable to the masses. Ensure critical clinical validations for every outcome. Bio-materials with high specificity, efficiency and sensitivity. Scientific disciplines with interdisciplinary intelligence at the core. Take every little step to ensure cancer patient’s lives are saved. Detect cancer relapse early, when it can be cured. We are committed to bringing stakeholders together to adopt innovative, safe, and effective technologies that can transform cancer care. Focused on creating novel cancer diagnostic tests. Know more Rigour in every action. Every product undergoes intense design and development. Leaving no stone unturned. We follow the most stringent quality norms like ISO13485 and regulatory requirements. Passionate and emphatic. We are committed to developing solutions for unmet medical needs. We build high-risk innovative products, which have a very long life-cycle, using novel biomaterials. With collaboration with knowledge leaders Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test

Access research manuscripts and scientific contributions from Actorius highlighting advances in oncology research, CTC detection, and liquid biopsy technologies. Manuscripts Research That Shapes the Future of Oncology Access studies, scientific papers, and published findings advancing cancer diagnostics and care. 27 January 2026 Read More Manuscript: Real-Time Therapy Response Monitoring Using Surface Biomarkers on Circulating Tumor Cells Circulating tumor cells (CTCs), cancer cells shed from primary tumors into the bloodstream, are emerging as dynamic, non-invasive biomarkers for real-time cancer monitoring, especially when tissue biopsies are inaccessible or inadequate... 14 March 2025 Read More Manuscript: The impact of co-occurring tumor suppressor mutations with mEGFR as early indicators of relapse in lung cancer A set of 17 co-occurring TSG mutations has been identified as key biomarkers for early relapse in mEGFR lung adenocarcinoma. Longitudinal genomic monitoring, with a focus on clonal evolution, offers valuable insights that can inform personalized treatment strategies and potentially improve patient outcomes. 15 July 2024 Read More Manuscript: Inverse 3D ‘lab-on-a-chip’ polymeric microfilms for selective capture of circulating tumor cells from patients' blood Inverse 3D lab-on-chip microfilms for selective CTC capture from blood. 29 June 2024 Read More Manuscript: Circulating Tumor Cells as Biomarkers for Relapse Detection in Rectal Cancer with Liver Metastasis: Insights from a Case Report In this case report we demonstrate the utility of CTC as a sensitive marker to detect MRD. CTCs play a crucial role in the context of MRD in colorectal cancer, offering a valuable biomarker for prognosis, treatment monitoring, and early detection of recurrence. 4 April 2024 Read More Manuscript: CTC together with Shh and Nrf2 are prospective diagnostic markers for HNSCC Study links Shh/Nrf2 overexpression with circulating tumor cells in HNSCC, highlighting their potential as biomarkers for early detection and survival prediction. 20 September 2023 Read More Manuscript: Magnetically-activated, nanostructured cellulose for efficient capture of CTCs from the blood sample of head and neck cancer patients Study compares CNC and CNF cellulose nanostructures for EpCAM-based CTC capture in head and neck cancer, enabling affordable real-time cancer monitoring. 20 July 2023 Read More Manuscript: Role of circulating tumour cells (CTCs) in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) This study highlights the utility of CTCs as a disease progression monitoring tool in recurrent HNSCC patients. Our findings suggest the potential clinical utility of CTCs and the need for further exploration in upfront settings of the disease as well (NCT: CTRL/2020/02/023378). 11 April 2023 Read More Manuscript: Chemical tunability of advanced materials used in the fabrication of micro/nanobots Review on chemically tunable micro- and nanobots for targeted nanomedicine, highlighting AI materials, applications, and biosafety considerations. 1 July 2022 Read More Manuscript: Circulating tumor cells as a predictor for poor prognostic factors and overall survival in treatment nay¨ve oral squamous cell carcinoma patients Preoperative circulating tumor cell levels strongly correlate with metastasis, disease severity, and reduced survival in oral squamous cell carcinoma patients. 27 April 2022 Read More Manuscript: Bioinspired Materials for Wearable Devices and Point-of-Care Testing of Cancer Raj Shankar Hazra, Md Rakib Hasan Khan, Narendra Kale, Tabassum Tanha, Jayant Khandare, Sabha Ganai, and Mohiuddin Quadir* 18 February 2022 Read More Manuscript: Antibody mediated cotton-archetypal substrate for enumeration of circulating tumor cells and chemotherapy outcome in 3D tumors Cotton microfluidic substrate enables efficient CTC isolation, 3D tumor growth, and drug response testing for improved cancer diagnostics and therapy research. 18 December 2020 Read More Manuscript: Chemo-specific designs for the enumeration of circulating tumor cells: advances in liquid biopsy Review on chemo-specific nano/micro substrates for efficient CTC isolation, enabling liquid biopsy, metastasis detection, and real-time cancer monitoring. 10 October 2020 Read More Manuscript: Cellulose Mediated Transferrin Nanocages for Enumeration of Circulating Tumor Cells for Head and Neck Cancer Magnetic transferrin-functionalized cellulose nanocages capture circulating tumor cells from blood, enabling liquid biopsy for early metastasis detection in head and neck cancer. 11 February 2018 Read More Manuscript: Optimizing Circulating Tumor Cells’ Capture Efficiency of Magnetic Nanogels by Transferrin Decoration Magnetic nanogels with optimized PEG–transferrin linkers achieve over 80% efficiency in selectively capturing circulating tumor cells from blood. 17 January 2018 Read More Manuscript: Selective Cell Isolation by Transferrin Functionalized Silane– Carbon Soot Mediated Superhydrophobic Micropatterns Transferrin-functionalized wettability micropatterns enable selective cancer cell capture and real-time monitoring for diagnostics and recurrence detection. 17 January 2017 Read More Manuscript: Biofunctionalized Capillary Flow Channel Platform Integrated with 3D Nanostructured Matrix to Capture Circulating Tumor Cells Continuous-flow 3D microchannel platform captures circulating tumor cells with ~90% efficiency, enabling liquid biopsy and real-time cancer monitoring. 17 April 2015 Read More Manuscript:Calcium phosphate nanocapsule crowned multiwalled carbon nanotubes for pH triggered intracellular anticancer drug release Calcium phosphate–capped carbon nanotubes enable pH-triggered intracellular release of doxorubicin, preventing premature drug leakage and improving targeted cancer therapy. 13 April 2015 Read More Manuscript: Self-propelled Carbon Nanotube Based Microrockets for Rapid Capture and Isolation of Circulating Tumor Cells Self-propelled CNT microrockets rapidly capture and magnetically isolate circulating tumor cells, enabling faster liquid biopsy and early cancer detection. Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test First Prev 1 Page 1 Next Last

Literature Product Resources Explore OncoDiscover® brochures, guides, and technical documents to learn more about the technology, science, and clinical applications behind our solutions. First Prev 1 Page 1 Next Last 9 March 2026 View document OncoDiscover PD-L1 whitepaper 9 March 2026 View document OncoDiscover Brochure 9 March 2026 View document OncoDiscover TRF Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test

CTCs and PD-L1 profiling support MRD detection and therapy decisions in ovarian cancer. Publications 3 June 2024 ASCO 2024: Effect of circulating tumor cells (CTC) and CTC clusters with PD-L1 dynamic biomarker on cellular burden in patients with ovarian cancer. CTCs with PD-L1 expression in ovarian cancer reveal minimal residual disease and may guide immunotherapy and early metastasis monitoring. Background In the precision oncology era, monitoring treatment response using circulating blood-based biomarkers such as circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) is rapidly being evaluated and established. The leading cause of mortality in ovarian cancer patients is delayed diagnosis and the inability to effectively select patients for targeted therapies, including immune checkpoint blockade (ICB) agents. Treatment for ovarian cancer usually involves a combination of surgery and chemotherapy. However, postoperative resection and therapy with curative intent often fail to account for minimal cellular disease (MCD). The dissemination of circulating tumor cells (CTCs) represents minimal residual disease (MRD), which may diffuse and cause micro-metastasis through epithelial-to-mesenchymal transition (EMT) and bio-mechanistic activation in blood circulation. Simultaneous detection of overexpression of programmed death-ligand 1 (PD-L1) on CTCs as a dynamic biomarker may be useful for assessing patients for immune checkpoint inhibitor (ICI) therapy. Methods In a retrospective analysis of real-world data, peripheral blood samples from 75 ovarian cancer patients were analyzed for the presence of CTCs, with and without PD-L1 expression, and for the presence of CTC clusters. CTCs were detected using the CDSCO-approved OncoDiscover platform from 1.5 ml of peripheral blood. The platform is a multifunctional magneto-nanosystem mediated by anti-epithelial cellular adhesion molecule (EpCAM) antibodies. CTCs were identified as positive when EpCAM+, CK+, PD-L1+, DAPI+, and CD45- markers were present. PD-L1 expression on CTCs was analyzed based on the linear intensity gradients of fluorescence signals using image acquisition on an automated Zeiss microscope. Results Baseline sample analysis showed that 86% (n = 65) of patients had at least one CTC per 1.5 ml of blood. The CTC distribution ranged from 1 to 9 CTCs. Among the patients with CTCs, 46.15% (n = 30) showed PD-L1 expression. Notably, the highest number of CTCs (~26.7%, n = 23) was observed in the 41–50 age group. Additionally, 8% (n = 6) of the total patients showed the presence of CTC clusters. The presence of CTCs with PD-L1 expression and CTC clusters did not show a correlation with factors such as staging, follow-ups, metastasis, or disease-free survival (DFS) status. Conclusions We observed the presence of minimal cellular disease (MCD) and minimal residual disease (MRD) in ovarian cancer patients despite treatment with curative intent. Detection of CTCs, CTC clusters, and PD-L1 overexpression as real-time dynamic biomarkers may help assess early metastasis, disease progression, and regression. These biomarkers may also support the selection of patients suitable for immune checkpoint inhibitor (ICI) therapy when tissue samples are inadequate or unavailable, potentially improving clinical outcomes. Know more Never Miss a Breakthrough. Get the latest news and innovations from OncoDiscover delivered straight to your inbox. Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test

Comprehensive ctDNA and CTC profiling predicts metastasis in early breast cancer. Publications 15 January 2023 AACR 2023: Abstract PR007: Comprehensive ctDNA profiling reveals potential metastatic genomic signatures in treatment-naive early-stage breast cancer patients Comprehensive ctDNA profiling and CTC analysis in early-stage breast cancer identifies driver mutations to predict early metastasis. Background Genomic profiling has revolutionized precision oncology, impacting diagnosis, prognosis, and therapy decisions. Considering the high spatiotemporal diversity and heterogeneity of breast tumor-cell genomes, small-gene panels often fail to capture rare but important genomic alterations. Conversely, comprehensive ctDNA sequencing approaches enable the identification of under-characterized 'long-tailed driver' genomic alterations and capture intra- and inter-metastatic heterogeneity. Here, we demonstrate the clinical utility of comprehensive genome profiling with higher sensitivity to predict the possibility of metastasis in early-stage breast cancer patients. Methods We retrospectively analyzed ctDNA and genomic DNA (gDNA) from FFPE samples, as well as circulating tumor cells (CTCs), in 10 treatment-naive, hormone-positive, and HER2-negative primary-stage breast cancer patients using the OncoIndx comprehensive 600-gene panel. The panel captures all important cancer-relevant genomic alterations, including tumor mutation burden (TMB), microsatellite instability (MSI), homologous recombination deficiency (HRD) prediction, and cfDNA tumor fraction (TF). CTCs were enumerated from 1.5 ml of blood using the OncoDiscover platform, approved by the Drug Controller General of India, using anti-EpCAM antibody-mediated immunomagnetic nanoparticles. CTCs were confirmed for cytokeratin 18+ and DAPI+ markers, and the absence of CD45. Results The comprehensive genomic profile obtained from ctDNA and gDNA from the FFPE of early-stage breast cancer patients predominantly exhibited the presence of alterations in PIK3CA and ESR1 signaling pathways. PIK3CA mutations were present in 77% and 44% of baseline ctDNA and gDNA samples, while ESR1 mutations were present in 44% and 22% of baseline ctDNA and gDNA, respectively. In addition, we observed about 70% additional driver mutations in ctDNA samples, suggesting the shedding of ctDNA together with CTCs (80% positive) as a likely positive biomarker of metastasis. About 50% of the patients showed higher TMB and HRD. Notably, TF representing ctDNA varied between 13% to 27% in blood samples with a corresponding ploidy range of 2.9 to 4.7. Surprisingly, ~50% of the patient population matched the mutation profile of clinically confirmed metastatic patients. All the patients harboring potential metastatic driver alterations showed the presence of CTCs in peripheral blood. Conclusions Comprehensive ctDNA genomic profiling showed potential metastasis-driving alterations, suggesting the role of ctDNA-based liquid biopsy to predict metastasis in early breast cancer patients. We observed enhanced TF at the time of diagnosis, possibly due to the presence of distant metastasis, high disease burden, and aggressive tumor biology. Our results suggest that ctDNA dynamics at the time of disease presentation can predict early metastasis and may demonstrate the divergent response of tumor heterogeneity to treatment in early-stage breast cancer. Know more Never Miss a Breakthrough. Get the latest news and innovations from OncoDiscover delivered straight to your inbox. Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test

CTCs, clusters, and PD-L1 expression indicate MRD and guide endometrial cancer care. Publications 3 November 2025 PD-L1 over-expression on Circulating Tumor Cells in Endometrial Cancer Patients Khandare J, Ghadyalpatil N, Raja T, Velukuru S, Jadhav V, Satape R, Shinde S, Ashturkar A, Dattatreya P, Vasudevan A Actorius Innovations And Research, Pune, Maharashtra, India; Apollo Cancer Institute, Hyderabad, Telangana, India; Apollo Cancer Centre, Chennai, Tamil Nadu, India; Aster CMI Hospital, Bangaluru, Karnataka, India; Renova Soumya Cancer Center, Hyderabad, Telangana, India. Introduction The risk of recurrence in non-metastatic endometrial cancer (EC) within 2–3 years is significant, ranging from 6% to 21%. Lymph node involvement is a key determinant of outcome prediction in patients with operable EC. To improve prognostic accuracy, particularly in the context of curative-intent surgery and adjunct therapy regimens, biomarkers such as circulating tumor cells (CTCs) have not been extensively evaluated in EC. The presence of CTCs as an occult disease component in EC may represent minimal cellular residual disease (MCRD) and could play a role in the metastatic cascade and invasion to distant organs. In this study, we evaluated the distribution of CTCs, their PD-L1 overexpression, and the occurrence of CTC clusters in EC patients. Methods A total of 154 blood samples were retrospectively analyzed, including 133 baseline and 21 follow-up samples (1.5 mL each). CTCs were isolated using the CDSCO India–approved OncoDiscover® CTC Test, which employs immunomagnetic enrichment targeting epithelial cell adhesion molecule (EpCAM). CTCs were identified based on immunocytochemical staining as CK18⁺, DAPI⁺, and CD45⁻ cells with distinct morphological features. Fluorescence imaging was performed using a Zeiss Axio Observer 7 microscope, and signal intensities were quantified to assess associations with clinicopathological parameters. PD-L1 expression on CTCs was evaluated through fluorescence-based immunostaining and quantified accordingly. Statistical analyses summarized total CTC counts, PD-L1–positive CTCs, and the presence of CTC clusters. Results A total of 336 CTCs were detected in 116 patients (75.3%). PD-L1 overexpression on CTCs was observed in 52.6% of samples (81 out of 154). Across all 154 patient samples analyzed, the mean values were 1.54 for total CTCs, 0.14 for CTC clusters, and 1.23 for PD-L1–positive CTCs. Notably, 21 patients (13.6%) demonstrated the presence of CTC clusters, accounting for 121 of the 336 total CTCs, suggesting more aggressive disease behavior. The highest proportion of patients belonged to the 61–70-year age group (41.55%). Conclusions This study demonstrates a high prevalence of CTCs in the endometrial cancer population. The presence of CTCs, CTC clusters, and PD-L1–overexpressing CTCs indicates occult minimal residual disease, disease aggressiveness, and potential progression toward metastasis. PD-L1 expression on CTCs may have implications for immunotherapy decision-making, particularly in situations where tissue biopsy is unavailable. View Publication Never Miss a Breakthrough. Get the latest news and innovations from OncoDiscover delivered straight to your inbox. Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test

OncoDiscover TRF Literature 9 March 2026 OncoDiscover TRF Test Requisition Form Download TRF Never Miss a Breakthrough. Get the latest news and innovations from OncoDiscover delivered straight to your inbox. Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test